Skip to main content

Table 7 Univariate survival analysis of clinico-pathological factors (unadjusted Cox proportional hazard model)

From: A population-based cohort study of chest x-ray screening in smokers: lung cancer detection findings and follow-up

  

A

 

B

 

C

  

n = 67

 

n = 245

 

n = 401

  

HR

 

HR

 

HR

  

(95% CI)

 

(95% CI)

 

(95% CI)

Gender

      

   Female

 

1.00

 

1.00

 

1.00

  

(reference)

 

(reference)

 

(reference)

   Male

 

1.42

 

0.85

 

0.91

  

(0.51-3.97)

 

(0.54-1.34)

 

(0.63-1.32)

Age at diagn. (+1 y)

 

1.01

 

1.01

 

1.01

  

(0.97-1.06)

 

(0.99-1.03)

 

(0.99-1.03)

Pack/years (+1)

 

1.00

 

1.00

 

1.00

  

(0.99-1.01)

 

(0.99-1.01)

 

(1.00-1.01)

Histology

      

   Adenocarcinoma

 

1.00

 

1.00

 

1.00

  

(reference)

 

(reference)

 

(reference)

   Squamous cell ca

 

1.37

 

0.97

 

1.19

  

(0.61-3.08)

 

(0.67-1.39)

 

(0.9-1.58)

   Other NSCLC

 

2.21

 

1.85 *

 

1.90 *

  

(0.74-6.62)

 

(1.15-2.97)

 

(1.29-2.79)

   SCLC

 

2.45 *

 

1.79 *

 

1.69 *

  

(1.00-6.1)

 

(1.12-2.86)

 

(1.17-2.46)

   CDO

 

5.60 *

 

2.22 *

 

2.44 *

  

(1.7-18.46)

 

(1.44-3.45)

 

(1.73-3.42)

Stage

      

   I

 

1.00

 

1.00

 

1.00

  

(reference)

 

(reference)

 

(reference)

   II

 

1.56

 

2.32 *

 

3.31 *

  

(0.19-12.98)

 

(1.07-5.05)

 

(1.85-5.92)

   IIIA

 

5.94 *

 

4.22 *

 

4.08 *

  

(1.93-18.26)

 

(2.37-7.53)

 

(2.56-6.51)

   IIIB - IV

 

14.02 *

 

8.38 *

 

8.35 *

  

(5.58-35.24)

 

(5.2-13.51)

 

(5.65-12.33)

Indeterminate

 

5.21

 

2.54 *

 

2.79 *

  

(0.61-44.11)

 

(1.29-5.02)

 

(1.51-5.13)

Unexposed

33 LCs

1.00

178 LCs

1.00

156 LCs

1.00

  

(reference)

 

(reference)

 

(reference)

Exposed

34 LCs

0.26 **

67 LCs

0.62 ***

245 LCs

0.69 ****

  

(0.14-0.49)

 

(0.44-0.86)

 

(0.55-0.87)

  1. Shown are (A) 67 lung cancers (LCs) of screening participants, (B) 245 LCs of the cohort, and (C) 401 LCs (156 of control group and 245 of cohort)
  2. HR: hazard ratio; CI: confidence interval; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; CDO: clinical diagnosis only; LC: lung cancer
  3. *P < 0.0001
  4. **P < 0.0001 (34 LCs Screen-detected vs. 33 LCs Nonscreen-detected)
  5. ***P = 0.0013 (67 LCs of Participants vs. 178 LCs of Nonparticipants)
  6. ****P = 0.002 (245 LCs of Cohort vs. 156 LCs of Control Group)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us